Latest / The BioHub - by Avetix
Episode 195 - Luke Henry - CBO/COO at Quell Therapeutics
Today, I'm delighted to welcome Luke Henry, Chief Business Officer and Chief Operating Officer at Quell Therapeutics, a company at the forefront of engineering the next generation of regulatory T cell, or Treg, therapies for immune-mediated diseases.
Quell is pioneering a new approach to treating autoimmune and inflammatory diseases, as well as improving outcomes in organ transplantation. Rather than suppressing the entire immune system, the company's engineered Treg therapies are designed to restore immune tolerance by precisely targeting the underlying immune dysfunction. Its platform…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.